Linda has over 20 years of sales and business development experience in
the biopharmaceutical industry in San Francisco, Boston, San Diego, and
Washington, D.C. Prior to starting 23andMe, she developed translational
research collaborations with academic and pharmaceutical partners for
Affymetrix and Perlegen Sciences. Linda also spent time at Spotfire
helping scientists understand the power of data visualization and at
Applied Biosystems during...
more
Linda has over 20 years of sales and business development experience in
the biopharmaceutical industry in San Francisco, Boston, San Diego, and
Washington, D.C. Prior to starting 23andMe, she developed translational
research collaborations with academic and pharmaceutical partners for
Affymetrix and Perlegen Sciences. Linda also spent time at Spotfire
helping scientists understand the power of data visualization and at
Applied Biosystems during the early days of the human genome project.
The advent of high density genome-wide scanning technologies brought
huge potential for significant discoveries. However, the lack of
sufficient funding to enable adequate studies prompted Linda to think
of a new research model. These ideas led to the formation of 23andMe.
Her primary interest is the acceleration of personalized medicine,
using genetic profiles to target the right drug to the right person at
the correct dose. Linda graduated from Augustana College with a B.A. in
biology.
less
